Encaleret Increased Bone Turnover and Improved Participant-Reported Symptoms in the Phase 3 CALIBRATE Trial in ADH1
Go back to Encaleret Increased Bone Turnover and Improved Participant-Reported Symptoms in the Phase 3 CALIBRATE Trial in ADH1| (NASDAQ: BBIO) | Delayed: 67.74 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $67.74 | 52 Week High | $ | |||
| Open | $67.74 | 52 Week Low | $ | |||
| Day High | $67.74 | P/E | N/A | |||
| Day Low | $67.74 | EPS | $ | |||
| Volume | 8 | |||||



